SCHEMBL4287418

SCHEMBL4287418

Cc1ccc(OCC[C@@H]2CN(C(=O)O)CCN2C(=O)O)c(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.47
GAA P10253 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
PPARG P37231 1/20 0.43
NPSR1 Q6W5P4 1/20 0.41
ALDH1A1 P00352 5/20 0.41
MEN1 O00255 1/20 0.41
HPGD P15428 1/20 0.41
KMT2A Q03164 1/20 0.41
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HTT P42858 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
TSHR P16473 1/20 0.40
MRGPRX4 Q96LA9 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 2/20 0.40
RAB9A P51151 1/20 0.39
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4285755 0.89 KDM4E (0.51) KDM4ETDP1NPSR1ALDH1A1MEN1
SCHEMBL4293913 0.87 DRD3 (0.45) KDM4ENPSR1ALDH1A1MEN1HPGD
SCHEMBL4284003 0.87 HCRTR1 (0.41) KDM4EGAATDP1ALDH1A1HPGD
SCHEMBL4283481 0.84 MEN1 (0.47) KDM4EGAAALDH1A1MEN1HPGD
SCHEMBL4283120 0.83 CYP1A2 (0.43) KDM4EGAAPPARGNPSR1ALDH1A1
SCHEMBL4289383 0.82 RAB9A (0.43) KDM4EGAANPSR1ALDH1A1MEN1
SCHEMBL4281983 0.82 L3MBTL1 (0.48) KDM4EGAATDP1ALDH1A1MEN1
SCHEMBL4286355 0.81 HCRTR1 (0.44) KDM4EGAATDP1NPSR1ALDH1A1
SCHEMBL4290199 0.80 HCRTR1 (0.41) KDM4EPPARGNPSR1ALDH1A1MEN1
SCHEMBL4297224 0.80 SYK (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
WO-2008139941-A1 SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156612-A1 Substituted imidazole compound and use thereof REN, ACE, AGT KDM4E 760/4885GAA 1381/4885TDP1 2253/4885
US-20090227560-A1 Substituted imidazole compound and use thereof REN, ACE, AGT KDM4E 760/4885GAA 1381/4885TDP1 2253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.